Deferasirox for managing iron overload in people with thalassaemia (Q24203718)

26 October 2023

3

Gerta Rücker

Gerta

Rücker

1 reference

26 October 2023

7

Dirk Bassler

Dirk

Bassler

1 reference

26 October 2023

2

Gerd Antes

Gerd

Antes

1 reference

26 October 2023

Joerg J Meerpohl

1

Joerg J

Meerpohl

1 reference

26 October 2023

4

Nigel Fleeman

Nigel

Fleeman

1 reference

26 October 2023

Charlotte M Niemeyer

6

Charlotte M

Niemeyer

1 reference

22336831

Cochrane Database of Systematic Reviews

26 October 2023

language of work or name

1 reference

15 February 2012

0 references

published in

0 references

cites work

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Global epidemiology of hemoglobin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Survival and complications in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Overcoming the challenge of patient compliance with iron chelation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Long-term efficacy and safety of deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferasirox pharmacokinetics in patients with adequate versus inadequate response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Results of long-term iron-chelating therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Acute renal failure and Fanconi syndrome due to deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Role of deferiprone in chelation therapy for transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferasirox for transfusion-related iron overload: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Global epidemiology of haemoglobin disorders and derived service indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

21 January 2018

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

21 January 2018

Deferasirox: an update

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Fanconi syndrome due to deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

The hemoglobinopathies and malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Oral deferiprone for iron chelation in people with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Thalassemia intermedia: revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Iron chelation adherence to deferoxamine and deferasirox in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Deferasirox--an oral agent for chronic iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Aggregate data meta-analysis with time-to-event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Survival and causes of death in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Some problems with the investigation of noninferiority in meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Thalassemia in the next millennium. Keynote address.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Secondary iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Deferasirox versus deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Does liver biopsy overestimate liver iron concentration?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007476.PUB2

7 January 2021

10.1002/14651858.CD007476.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_3zfp5ojzfzdkxfn5apatqdc3su

0 references